in vivo Allo Cell Therapy or iACT™ utilizes our next-generation oncolytic vaccinia virus to reprogram tumor cells in vivo to express a foreign cassette. Tumors activate abundant T cells to infiltrate the tumor micro–environment, effectively turning tumors into a transplanted organ or a graft.
Tumors re-programmed in vivo to express a foreign cassette also become susceptible to TCR-T without dependence on the patient’s haplotype.